Communiqués Madrigal Pharmaceuticals, Inc. NYSE

Actions

US5588681057

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX Autres places de cotation 13:00:15 23/07/2026			Varia. 5j.	Varia. 1 janv.
532,56 ^USD	0,00%		0,00%	-

22/07	MADRIGAL PHARMACEUTICALS, INC. : BofA Securities à l'achat	ZM
21/07	Madrigal Pharmaceuticals : un dirigeant cède pour 1 368 253 $ d'actions, selon un document de la SEC	MT

Communiqués

21/07	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
16/07	Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026	AQ
13/07	Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio	AQ
06/07	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
22/06	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
04/06	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
03/06	Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026	AQ
27/05	Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH	AQ
21/05	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
20/05	Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk	AQ
07/05	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
06/05	Madrigal Pharmaceuticals : MDGL 1Q26 Earnings Presentation	PU
06/05	Madrigal Pharmaceuticals : 1Q26 Press Release Final	PU
06/05	Madrigal: Q1 Earnings Snapshot	AQ
06/05	Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates	AQ
05/05	Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline	AQ
22/04	Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026	AQ
21/04	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
07/04	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
19/03	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
05/03	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
24/02	Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference	AQ
19/02	Madrigal Pharmaceuticals : MDGL 4Q25 Earnings Presentation 02.19.26	PU
19/02	Madrigal: Q4 Earnings Snapshot	AQ
19/02	Madrigal Pharmaceuticals : 4Q25 Press Release 02.19.26	PU